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The lack of the Celf2a splicing factor converts a
Duchenne genotype into a Becker phenotype
J. Martone1,*, F. Briganti1,*, I. Legnini1, M. Morlando1, E. Picillo2, O. Sthandier1, L. Politano2 & I. Bozzoni1,3,4
Substitutions, deletions and duplications in the dystrophin gene lead to either the severe
Duchenne muscular dystrophy (DMD) or mild Becker muscular dystrophy depending on
whether out-of-frame or in-frame transcripts are produced. We identified a DMD case
(GSD44) where the correlation between genotype and phenotype is not respected, even if
carrying a typical Duchenne mutation (exon 44 deletion) a Becker-like phenotype was
observed. Here we report that in this patient, partial restoration of an in-frame transcript
occurs by natural skipping of exon 45 and that this is due to the lack of Celf2a, a splicing
factor that interacts with exon 45 in the dystrophin pre-mRNA. Several experiments are
presented that demonstrate the central role of Celf2a in controlling exon 45 splicing; our data
point to this factor as a potential target for the improvement of those DMD therapeutic
treatments, which requires exon 45 skipping.
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D
uchenne muscular dystrophy (DMD) is a rare neuro-
muscular disease characterized by substitutions, deletions
and duplications in the dystrophin gene leading to
frameshift and premature translation termination1. Dystrophin
is a cytoskeleton protein which stabilizes the dystrophin-
associated protein complex, required for muscle fibre integrity2,
and controls gene expression through nNOS activation and
nitric oxide-mediated HDAC2 inactivation3–5. At variance with
DMD, the milder form of the disease, the Becker muscular
dystrophy (BMD), is caused by mutations, including long
deletions, which do not perturb the open reading frame (ORF)
integrity and produce shorter and partially functional dystrophin
isoforms. Deletions in the dystrophin gene are found inB68% of
DMD patients, with the region including exons 44–55 being the
most commonly mutated, together with the one encompassing
exons 2–20 (ref. 6). However, the severity of the pathology is not
always predictable by exon deletion, suggesting that each patient
has specific deletion breakpoints that may differentially affect
splicing. Moreover the ‘reading frame model’, in which BMD
patients produce a semi-functional, internally deleted dystrophin
protein, whereas DMD patients have no detectable protein, is not
always respected7,8. Uncertainty in predicting the Duchenne/
Becker pathology indicates that the clinical picture should always
be accompanied by a detailed molecular analysis, including
transcript structure and dystrophin-associated proteins. Several
data indicated that altered splicing patterns in a collection of
BMD patients do not directly result from the gene defect but
probably derive from modifications in trans- rather than
cis-acting factors9.
The fact that BMD patients carrying extended deletions display
only mild phenotypes, suggested that manipulating the splicing of
the dystrophin pre-mRNA, to induce the skipping of specific
exons and restore a correct reading frame, could be a powerful
strategy for DMD treatment10–13. This approach has recently
entered into clinical trials through the use of antisense
oligonucleotides preventing exon recognition by the splicing
machinery14,15.
In this work we have studied a DMD case (GSD44), in which
the correlation between genotype and phenotype is not respected:
even if the genetic analysis of the dystrophin gene locus showed a
deletion of exon 44, which should normally lead to DMD, the
patient is now 18 years old and can still walk independently.
Molecular analyses on both GSD44 biopsy and primary myoblasts
showed the presence of tiny but consistent dystrophin levels due
to endogenous skipping of exon 45. We describe here that this
phenotype is due to the lack of the Celf2a protein isoform, that we
found to enhance exon 45 inclusion.
Results
A DMD patient produces dystrophin by natural exon skipping.
An individual (GSD44) with a DMD genotype (deletion of exon
44 which leads to an out-of-frame transcript) was under study
since, quite surprisingly, his clinical and behavioural tests were in
agreement more with a Becker phenotype, even if of a severe type.
Supplementary Table 1 summarizes the timed tests from the age
of 5 to 18: while DMD patients normally lose ambulance around
the age of 12 and need ventilatory support at their late teens,
GSD44 is 18 years old and, even if he has lost the ability to stand
up from the ground, he can walk and breath normally.
A muscle biopsy, performed at the age of 15, indicated the
unexpected presence of dystrophin at low but well detectable
levels (Fig. 1a). As expected for a dystrophic sample16
regeneration was occurring: the early myogenic factor
myogenin (MYOG) was still expressed, while the terminal
differentiation markers, myosin heavy chain (MHC) and muscle
creatin kinase (MCK)17, were lower with respect to the biopsy
from a healthy control (Fig. 1b,c). Regeneration was also
indicated by sustained expression of the proliferative miR-31
and by reduced levels of miR-1 and miR-133, markers of mature
muscle fibres18 (Fig. 1c). Since muscle biopsies can vary
considerably on the basis of the inflammatory and fibrotic state
of the tissue, we derived a culture of primary myoblasts and
analysed dystrophin expression upon differentiation in low
serum, in parallel to control myocytes derived from a healthy
individual. In agreement with the biopsy sample, in vitro
differentiation confirmed the ability of GSD44 myocytes to
produce dystrophin (Fig. 1d). A scaled dilution of proteins from
controls indicated that these levels corresponded toB7% of those
found in healthy myocytes. Interestingly, such low levels of
dystrophin paralleled a slower timing of differentiation16,19: in
fact, myogenin expression was still detectable at day 10, while
MHC was reduced in comparison with control (Fig. 1d). This is
in line with the notion that dystrophic cultures show a slower
progression into the differentiation process16, with BMD having
on average a less severe differentiation phenotype than DMD20,21.
A detailed mapping of the GSD44 deletion revealed a 4065 bp
deletion, encompassing exon 44, with the fusion between
nucleotide 69586 of intron 43 and nucleotide 3038 of intron
44 (Supplementary Fig. 1a–c and Supplementary Methods).
Therefore, we confirmed the DMD genotype of GSD44.
Reverse transcription PCR (RT–PCR) analysis on RNA from
the GSD44 biopsy and from myocytes derived from primary
myoblasts indicated that in addition to the lack of exon 44,
a small fraction of transcripts also skipped exon 45 (Fig. 1e).
Sequencing of this product confirmed the skipping of exon 45
and the proper fusion between exon 43 and exon 46 (not shown),
giving rise to an in-frame transcript coding for a shorter but
functional protein21,22. Notably, the skipping of exon 45 is
currently conceived as a possible approach for the therapeutic
treatment of D44 deletions and for those DMD mutations that
through exon 45 skipping could recover the correct reading
frame22. The presence of sub-optimal splice junctions in exon 45
of the DMD gene of GSD44 was excluded by PCR amplification
and sequence analysis of the genomic DNA (data not shown).
Because of the limited ability of in vitro propagation of primary
myoblasts, fibroblasts derived from the GSD44 biopsy and
trans-differentiated with MyoD towards the myogenic lineage21
were also used. These cells produced exon 45 skipping and
dystrophin synthesis similarly to differentiated primary
myoblasts, even if with a delayed time of expression (Fig. 2a
and Supplementary Fig. 2a). Notably, two different trans-
differentiated D44 DMD myocyte cultures, carrying unrelated
deletions around exon 44 (D44-1 and D44-2), did not show any
detectable exon 45 skipping (Fig. 2a).
GSD44 myoblasts lack the Celf2a splicing factor. RNA-seq
experiments, performed on healthy control, GSD44 and D44-1
myoblasts and myocytes (deposited at Gene Expression Omnibus,
GSE70389), were queried for the abundance of splicing enhancers
(SRSF1, SRSF2, SRSF5 and SRSF6) whose potential binding
motifs were identified on exon 45 by using the ESE Finder tool
(ref. 23 and Supplementary Fig. 2b). This analysis indicated that
abundance of such mRNAs did not vary among the different
samples; finding that was validated by RT–PCR (Supplementary
Fig. 2c). Therefore, none of these factors could be considered a
good candidate for the expected phenotype.
Other possible candidates, among the factors previously known
to change during muscle differentiation, were searched. Among
them, the CUGBP, Elav-like family member 2 (Celf2) protein was
demonstrated to regulate various processes including alternative
splicing, editing, RNA stability and translation24–29 and suggested
to participate in dystrophin splicing9. CELF2 is composed of
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three isoforms differing by their first exon (exons 1a, 1b and 1c)9,
that are here termed CELF2a, b and c, respectively
(Supplementary Fig. 2d); moreover, CELF2a has a variant
isoform consisting in the alternative use of a 18 nt extended
exon 11 (ref. 28). Analysis of CELF2 transcripts in the RNA-seq
of control, GSD44 and D44-1 samples indicated that while the
CELF2b and CELF2c isoforms were expressed in all samples,
CELF2a was completely absent in GSD44 both in growth (GM)
and differentiation (DM) conditions.
The absence of CELF2a mRNA, was validated by RT–PCR
both in the biopsy sample (Fig. 2b) and in myoblasts (GM) and
myocytes (DM) of GSD44 (Fig. 2c). Notably, all three isoforms
were instead present in control and D44-1 cells (Fig. 2c). Western
blot analysis with commercially available antibodies indicated
their inability to distinguish between the three different isoforms
(Supplementary Fig. 2e); therefore, in following analyses CELF2
isoform expression was always tested at the RNA level.
When analysing trans-differentiated fibroblasts of GSD44’s
parents, it was interesting to find that while CELF2a is present in
the father, the mother specifically lacks this isoform (Fig. 2d) and
displays skipping of exon 45 (Supplementary Fig. 2f). In her case,
the skipped product is present at very low levels since exclusion of
exon 45 would produce an out-of-frame transcript that undergoes
degradation through the NMD pathway.
A 1.3 kb DNA sequence upstream the TSS and 200 nt of the
first exon/intron of CELF2a was sequenced in the GSD44 DNA.
We identified only two variants of annotated single-nucleotide
polymorphisms (chr10:11046386 T/C, chr10:11047206 C/G of the
hg19 human assembly), one of which was laying at the border of a
CpG island; neither sequence corresponded to obvious transcrip-
tional factor binding sites as checked on the Encode Transcrip-
tional factors binding tracks at UCSC genome browser and on
TransFac database. To check whether methylation could affect
CELF2a expression, GSD44 myoblasts were treated for 7 days
with 5-azacytidine in parallel with control myoblasts. No rescue
of CELF2a expression was obtained in treated versus untreated
GSD44 cells, suggesting that likely promoter methylation is not
the cause of CELF2a lack in these cells (Supplementary Fig. 2g).
Also in control cells, 5-azacytidine treatment did not affect
CELF2a levels (Supplementary Fig. 2g and Supplementary
Methods).
To detect similar exon skipping events possibly related to the
absence of CELF2a, the RNAseq data obtained from control, D44
and GSD44 myoblasts and myocytes were analysed by MATS
(ref. 30). Ratios of exon inclusion/skipping were compared
in GSD44 versus D44-1 and in GSD44 versus control
(Supplementary Table 2 and Supplementary Data 1). To exclude
exon skipping events related to the pathological state or to altered
differentiation of DMD cells, we selected only those that were
concordant and significant in both GSD44 versus control and
GSD44 versus D44-1. Out of 29 genes, correlating with the lack
of CELF2a (Supplementary Table 2), five transcripts exhibited
DYS
ACTN
GS
Δ4
4 GS
Δ4
4
CT
RL
a
MHC
MCK
ACTN
MYOG
CT
RL
c
DYS
MHC
MYOG
ACTN
80 μg0.5 μg1 μg5 μg20 μg
GSΔ44CTRL
100% 7%
100% 82%
100% 30%26%
d
0
1
2
MCK
0
1
2
MYOG
0
1
2
miR-1
0
1
2
miR-133
0
1
2
DMD
0
1
2
CTRL
GSΔ44
MHC
miR-31
0
50
100
e
R
el
at
iv
e 
ex
pr
es
sio
n
b
CT
RL
ORF restored
ORF interrupted
WT ORF
E4
3
E4
4
E4
5
E4
6
E4
3
E4
6
M
ORF restored
ORF interrupted
WT ORF
M E
43 E4
4
E4
5
E4
6
E4
3
E4
6
CT
RL
G
SΔ
44
G
SΔ
44
1,000 nt
200 nt
300 nt
750 nt
Figure 1 | Expression of dystrophin and myogenic markers in GSD44 biopsy and primary myoblasts. (a,b) Western blot on proteins (20 mg) extracted
from human muscle biopsies of a healthy control (CTRL) and from GSD44 probed with antibodies against dystrophin (DYS, a), or myogenin (MYOG),
MHC and muscle creatine-kinase (MCK, b). Actinin (ACTN) was used as a loading control. (c) Quantitative RT–PCR of myogenic markers and myomiRs
performed on RNA extracted from healthy control (CTRL) and GSD44 muscle biopsies. Bar plots show relative expression levels with respect to control set
to 1: values were normalized with GAPDH and hypoxanthine phosphoribosyltransferase (HPRT) for mRNAs and with U6 and miR-16 for miRNAs. Bars
indicate a confidence level of 95%. (d) Western blot on proteins extracted from healthy control (CTRL) and GSD44 primary myoblasts upon 10 days of
shift to differentiation conditions and probed with antibodies against dystrophin (DYS), myogenin (MYOG) and MHC. The amount of proteins loaded is
indicated below each lane. Actinin (ACTN) was used as a loading control. (e) Nested RT–PCR performed on RNA from biopsy samples (upper panel) and
differentiated myocytes obtained as in d (lower panel); 20 ng of cDNA were amplified with primers located in exons 42 and 53 and then with primers in
exons 43 and 46 (upper panel) and in exons 43 and 48 (lower panel). A schematic representation of the WT, interrupted and restored ORFs is shown on
the side. M, molecular weight marker: GeneRuler 100bp (Thermo Scientific) for the upper panel and GeneRuler 1 kb (Thermo Scientific) for the lower panel;
sizes are shown on the side.
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alternative splicing events in differentiated myocytes and two
of them were experimentally validated, CSDE1 and TMED2.
In comparison with control and D44-1, GSD44 shows the
preferential accumulation of skipped isoforms for both CSDE1
and TMED2 transcripts (Supplementary Fig. 2h,i).
Four unrelated BMD biopsies21 (Supplementary Fig. 2j) were
then analysed; they all expressed CELF2a and displayed the same
CSDE1 and TMED2 isoforms as the control sample (Fig. 2e). The
same isoforms’ pattern was also obtained in D44-1 myocytes
(Fig. 2f). In contrast, the GSD44 biopsy and myocytes, besides
lacking CELF2a, showed only the skipped isoforms for both
CSDE1 and TMED2 (Fig. 2e,f). Notably, while the isoforms
present in control and BMD are found in mature muscle fibres
(Supplementary Table 2), those present in GSD44 correspond to
more ubiquitous species31. In fact, comparison of CSDE1 and
TMED2 in wild-type (WT) and GSD44 fibroblasts and myoblasts,
indicated that only the unskipped species are the myocyte-specific
isoforms (Supplementary Fig. 2k). The skipped splicing variants
detected in GSD44 do not have premature stop codons and
maintain well-defined protein coding ability even if they are not
specific for muscle cells. From these data it cannot be excluded
whether any of these changes in isoform ratio could have
secondary detrimental effects, even though GSD44 does not show
any adverse effect in any other specific physiological activity.
Celf2a affects exon 45 splicing. We next tested whether rescue of
Celf2a in GSD44 could affect exon 45 splicing. A Flag-CELF2a
construct (pFlag-CELF2a-1) or an empty vector (pcDNA) were
transfected into GSD44 myoblasts and exon 45 skipping was
analysed upon induction of differentiation. Efficient expression of
CELF2a was confirmed in GSD44 myocytes both at the RNA and
protein levels (Fig. 3a). Notably, under these conditions, exon 45
skipping was prevented (Fig. 3a). The same result was obtained
when using a plasmid encoding for the CELF2a variant, lacking
the 18 nt extension in exon 11 (pCELF2a-2, Supplementary
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Figure 2 | GSD44 lacks the CELF2a isoform. (a) Fibroblasts from control (CTRL), two D44 unrelated DMD (D44-1 and D44-2) and GSD44 biopsies were
trans-differentiated into myocytes via infection with a lentivirus containing a MyoD-expression cassette. After 10 days in differentiation medium, RNA was
extracted and RT–PCR was performed with primers located in exons 43 and 46. M, molecular weight marker: GeneRuler 100bp (Thermo Scientific).
(b) RT–PCR for the three CELF2 isoforms on RNA from control (CTRL) and GSD44 biopsies. (c) MyoD-transduced fibroblasts from control (CTRL), D44-1
and GSD44 were maintained in growth conditions (GM) or shifted to differentiation medium (DM) for 10 days. RNA was extracted and analysed by
RT–PCR with oligos specific for the three CELF2 isoforms. (d) MyoD-transduced fibroblasts from the mother (M) and father (F) of GSD44 were induced to
differentiate and RNA analysed by RT–PCR for the three CELF2 isoforms. (e) RT–PCR for the three CELF2 isoforms and for CSDE1 and TMED2 mRNAs on
RNA from control (CTRL), GSD44 and 4 different BMD biopsies (BMD-3, BMD-10, BMD-15 and BMD-16). (f) RT–PCR for the three CELF2 isoforms and for
CSDE1 and TMED mRNAs on RNA from control (CTRL), D44-1 and GSD44 trans-differentiated myocytes. In all experiments GAPDH was used as control.
Molecular weight marker: GeneRuler 100bp (Thermo Scientific).
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Fig. 3a). Interestingly, the overexpression of either forms of
CELF2a did not produce any change in the splicing pattern of
CSDE1 and TMED2 (Fig. 3a) indicating that Celf2a has no effect
on these two substrates. These results open the interesting
question whether CELF2a, together with CSDE1 and TMED2, are
on a common pathway perhaps responding to a common
upstream effector.
To further analyse Celf2a splicing activity, D44-1 myoblasts
were infected with a lentiviral construct expressing shRNAs
against CELF2a and induced to differentiate for 10 days in the
presence of anti-CELF2a LNA GapmeRs. With respect to a 30%
decrease of CELF2a, a little amount of exon 45 skipping was
observed, indicating again the ability of this factor to impinge
specifically on exon 45 splicing in a myogenic environment
(Supplementary Fig. 3b and Supplementary Methods).
Celf2a activity was also tested on an artificial construct
(pLuc45, Fig. 3b) containing exon 45 and portions of the flanking
regions cloned inside the intron of pcDNA3.1-Luc (refs 32,33).
From pLuc45, luciferase can be produced only when exon 45 is
skipped. When GSD44 myoblasts were transfected with pLuc45, a
10-fold increase in luciferase activity with respect to control cells
was obtained (Fig. 3c). These data indicate that the absence of
CELF2a leads to exon 45 skipping also in this artificial construct
and that the regions included are sufficient to respond to Celf2a
activity. The effects of CELF2a absence were also tested in a
cellular context devoid of CELF2a, such as HeLa cells
(Supplementary Fig. 3c). Therefore, pLuc45 was transfected into
HeLa cells together with pFlag-CELF2a or with an empty vector
as control (pcDNA). The results show that while very little
luciferase activity is produced upon ectopic expression of CELF2a
(Supplementary Fig. 3d), in control cells luciferase levels increase
by four-fold (Fig. 3d).
Finally, to test whether Celf2a interacts with the region
containing exon 45, a cross-linking immunoprecipitation (CLIP)
assay was performed on nuclear RNA from control and GSD44
myocytes. As a positive control, the region inside intron 10
of the insulin receptor gene (IR), previously reported to bind
Celf2c (refs 25,34), was used. Figure 3e shows that, in control
myocytes (panel CTRL), Celf2 antibodies are able to immuno-
precipitate the region containing exon 45 of the dystrophin
pre-mRNA (E45) as well as a specific region inside intron 10 of
the IR transcript (IR-I10). No interaction was instead detected
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Figure 3 | CELF2a favours exon 45 inclusion. (a) GSD44 trans-differentiated myocytes were transfected with an empty vector (pcDNA) or with a
Flag-CELF2a construct (pFlag-CELF2a-1). Cells were shifted to DM medium for 10 days and the RNA analysed by RT–PCR for Flag-CELF2a expression, for
exon 45 skipping (43–46) and for CSDE1 and TMED2 isoforms (upper panel). The expression of the exogenous Flag-CELF2a was tested by western blot
with anti-FLAG antibodies (lower panel). GAPDH was used as loading control. (b) Schematic representation of the pLuc45 construct: the DMD gene region
encompassing exon 45 plus portions of the flanking introns was cloned into the intron of pcDNA3.1-Luc. This plasmid contains the CMV promoter driving
the expression of a Firefly luciferase pre-mRNA that produces luciferase only upon splicing (lower part). (c) The Bar plots show the relative luminescence
units (RLU) of Firefly luciferase in control (black bar) and GSD44 (grey bar) myoblasts transfected with pLuc45 and incubated 48 h. The values were
normalized for Renilla luciferase activity derived from a co-transfected pRL-TK plasmid. Error bars represent standard error from two independent
experiments. *Po0.05. (d) The Bar plots show the RLU of Firefly luciferase in HeLa cells transfected with pLuc45 and either pFlag-CELF2a-1 (dotted bar) or
pcDNA (dashed bar) and incubated 48 h. The values were normalized for Renilla luciferase activity derived from a co-transfected pRL-TK plasmid. Error
bars represent s.e.m. from three independent experiments. **Po0.01. (e) Left panel: schematic representation of part of the dystrophin (DMD) and insulin
receptor (IR) pre-mRNAs. Arrows indicate the positions of the oligos used. Right panels: control (CTRL) and GSD44 myocytes were UV crosslinked and
subjected to nuclear-cytoplasmic fractionation. Nuclear extracts were immunoprecipitated by anti-CELF2 (lane IP) and control IgG antibodies. The presence
of the regions indicated on the right (E45, E44–45 and E10 for DMD; IR-I10 for IR) was analysed by RT–PCR. GAPDH was used as negative control. ‘IN’
samples represent 10% of the total nuclear extract. Molecular weight marker: GeneRuler 100bp (Thermo Scientific). CMV, cytomegalovirus.
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on regions containing exon 10 (E10) of the dystrophin pre-
mRNA or when amplification of the spliced exons 44–45 (E44–
45) region was performed. Notably, when CLIP was performed
on GSD44 myocytes (panel GSD44), no signal was found on the
dystrophin exon 45 containing region, while interaction was
detected on intron 10 of the IR transcript (Fig. 3e). Since GSD44
myocytes express only the CELF2b and c isoforms, these results
indicate that exon 45 interaction in control cells is specifically due
to CELF2a. In conclusion, these data indicate that the Celf2a
isoform is able to interact with the dystrophin pre-mRNA at the
level of exon 45 and to enhance its inclusion during the splicing
reaction.
Discussion
The exon skipping strategy, as a therapeutic approach for DMD,
relies on the concept of converting severe Duchenne phenotypes
into milder Becker ones. In line with this, several studies have
shown that the disease course of BMD patients with a mutation
mimicking a ’skipped’ DMD mutation is relatively mild even
though BMD individuals display a large range of phenotypes35,
likely reflecting the ability of shorter dystrophin proteins to
accomplish only a subset of the different functions of the WT
full-length form8 and to be able to produce different amounts
of dystrophin. This strong variability stands for individual
heterogeneity likely including the specific deletion as well as
possible trans-acting factors9.
Moreover, one of the major concerns about the exon skipping
approach resides on how much dystrophin should be required in
order to be of therapeutic benefit. Here we show a DMD patient
case of a 18-year-old boy, with a D44 mutation; however, his
clinical features, are in net contrast with the common lost of
deambulation ability of DMD patients occurring around the first
decade of age. Surprisingly, GSD44 myocytes, through sponta-
neous exon skipping, produce 7% of dystrophin with respect to
control cells, indicating that this amount of dystrophin is enough
to alleviate the severity of the disease. Therefore, GSD44 is an
exemplary human case indicating that even very low levels of
dystrophin might provide milder dystrophic conditions. GSD44
presents an intermediate phenotype between a typical DMD
patient and a Becker individual, who can be asymptomatic for
several decades; in fact, GSD44 walks independently even if has
lost the ability to stand up from the ground. This is in line with
the finding that levels of dystrophin slightly higher than those of
GSD44 were found in a large cohort of BMD individuals35 and
required in mice to slow down or prevent disease progression and
improve overall muscle function36,37.
By transcriptome analysis of GSD44 myocytes, we discovered
the absence of CELF2a, a specific isoform of the Celf2 splicing
factor and we were able to correlate the absence of this product
with exon 45 skipping occurring in GSD44. CELF2 mRNA is
expressed at variable levels in BMD/DMD skeletal muscles and its
role in splicing regulation was previously suggested9. Celf2
belongs to the CELF/Bruno-like family of RNA-binding proteins
that, in mammals, contains six members. This family of highly
conserved proteins is involved in regulation of cell-specific and
developmentally regulated alternative splicing29. The highest
expression of CELF2 is found in heart, skeletal muscle and brain
and single-nucleotide mutations in this gene have been correlated
with a familial form of arrhythmogenic right ventricular28.
Since no mutations were found around the promoter and first
exon/intron regions of the GSD44 CELF2a gene, it is likely that
the genetic cause for its absence resides on upstream factors
regulating its biogenesis or to a still unidentified epigenetic
control. As other transcripts appear to be specifically affected in
GSD44 myocytes, it will be interesting to analyse whether they are
part of a common regulatory pathway specifically impinging on
muscle homeostasis.
Our data suggest that CELF2a inhibition could represents an
interesting new strategy to be considered for improving DMD
treatment, at least in those cases where the skipping of exon 45
would result in the recovery of mRNA with an ORF. A relevant
challenge for the future would be to design and set up genetic or
pharmacological treatments for interfering with Celf2a activity;
moreover, these results point to the relevance of studying the
genomic milieu of different patients in order to facilitate the
clinical development of personalized therapies.
Methods
Case report. The proband is a 18-year-old boy, the first child of non-con-
sanguineous Italian healthy parents. There was no family history of autoimmune or
musculoskeletal disorders in the family. The birth was at term, by caesarean
delivery. The baby presented neonatal jaundice treated by phototherapy. The child
has never crawled and has acquired independent walking at 18 months. At 1 month
of age he presented intolerance to breast milk so he began to take formula.
At 7 months he presented an episode of bronchospasm that required hospitali-
zation at the department of pediatrics of the local hospital. During hospitalization,
laboratory tests pointed out high levels of transaminases (GOT 797U l 1 and GPT
266U l 1) and creatin kinase (12622U l 1). Because this elevation, the family has
been addressed at the Cardiomyology and Medical Genetics of Second University
of Naples suspecting a muscle disorder, where he arrived at the age of 8 months. At
the first control, the baby did not show pseudo-hypertrophy of the calves, but given
the high values of the creatin kinase, a blood sample was carried out, with the
mother’s consent, to perform the molecular analysis of the dystrophin gene. The
analysis showed the isolated deletion of the exon 44, an out-of-frame mutation
consistent with a diagnosis of DMD. Since then, the child underwent regular
checks every 6 months, by the same clinical team. Despite the prognosis, the
evolution of the disease was very mild, at the age of 5 years the boy was still able to
stand up from the floor in 5 s, though showing the Gowers manoeuvre, and to
climbing stairs without support in 2 s. The electrocardiogram showed signs of
postero-lateral fibrosis, a picture typical of dystrophinopathic cardiomyopathy38
so that the administration of steroids (Deflazacort  0,75mg kg 1 day 1) and
Ace-inhibitors (Fosinopril 5mg day 1) was started, according to standard
protocol.
At the last control—at the age of 18 years—the boy walks independently, with a
waddling gait, but shows some difficulty in getting up from a chair and climbing
stairs. North Star (NSAA) has a value of 8/34 and he was able of walking 252m in
6min (6MWT). The electrocardiogram showed a progression of the fibrosis, while
echocardiography showed normal diameters and volumes of cardiac chambers,
normal thickness of septum and left posterior wall and a normal ejection fraction.
There was a mild reduction of the vital capacity values (FVC 2610ml, 61%).
Skeletal muscle biopsies. BMD-3, BMD-10, BMD-15, BMD-16 and control
skeletal muscle biopsies were obtained, with informed consent, from the
Laboratory of Molecular Medicine, Department of Neuroscience, Bambino
Gesu` Children’s Hospital, Rome whereas SGD44 biopsy was obtained from the
EuroBiobank and Telethon Neuromuscular Biobank of Second University of
Napoli.
Isolation of myoblasts from muscle biopsies. Muscle tissue was minced and
placed at 37 C for 45min, with gently shaking, in 20ml of phosphate-buffered
saline (PBS)-collagenase solution (1mgml 1). Resuspended solution was then
passed throught a 70 mm filter. After centrifugation (1500 r.p.m. for 10min at 4 C)
the pellet was resuspended in RPMI, 15% FBS, 1X P/S, plated in collagenate plates
and incubated at 37 C with 5% of CO2.
Cell cultures and treatments. WT (9208), D44-1 (9981) (from the Telethon
Network of Genetic Biobanks) and GSD44 human primary myoblasts were
cultured in Human skeletal muscle growth medium (PromoCell) and grown in a
humidified incubator, at 5% CO2 and 37 C. Cells were induced to differentiate
with human skeletal muscle differentiation medium (PromoCell). Transient
transfection of plasmids was carried out with the use of Lipofectamine-2000
(Invitrogen) according to the manufacturer’s specifications.
Reprogramming of fibroblasts into myoblasts. Conversion of fibroblasts into
myoblasts was achieved by ectopic expression of MyoD gene39,40 through lentiviral
infection.
Virus preparation and cell transduction. Viruses were prepared as described33.
Cells were transduced with 5 106 lentiviral particles for 5 h and harvested after
10 days of differentiation.
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DNA and RNA preparation. Cells were harvested in QIAzol Lysis Reagent
(Qiagen) and biopsies were homogenized with a rotor-stator homogenizer in the
presence of QIAzol Lysis Reagent (Qiagen). RNA was extracted by miRNeasy
(Qiagen), following manufacturer’s specifications; Genomic DNA was extracted
from the organic phase (interphase) of QIAzol Lysis Reagent (Qiagen) after
RNA preparation. Concentrations were assessed with Nanodrop ND-1000
Spectrophotometer (CELBIO; Pero, Milan, Italy).
Real-time PCR. cDNA generation was carried out using the miScript Reverse
Transcription Kit (QIAGEN). Real-time PCR detection of miRNAs and mRNAs
was performed using the miScript SYBR-Green PCR Kit and QuantiTect and
miScript Primer Assays (QIAGEN).
RT–PCR. Reverse transcription was performed on 300 ng of total RNA using
SuperScript VILO cDNA Synthesis Kit (Life Technologies) and PCR was
performed using MyTaq HS DNA Polymerase (Bioline). Oligonucleotides are
listed below.
4DMD E42F GAAGACATGCCTTTGGAAATTTCT
4DMD E43F CTACAACAAAGCTCAGGTCG
4DMD E46R CTCTTTTCCAGGTTCAAGTGG
4DMD E48R CTGAACGTCAAATGGTCCTTC
4DMD E53R TTGTACTTCATCCCACTGATT
4CELF2 E1aF CTATGAGAAATGAAGAGCTGC
4CELF2 E1bF GATTTCCTCCCGGACATGACG
4CELF2 E1cF CTCTGCTCGACAGCAGCACG
4CELF2 E2R GAGGACGTTGATCTGGTAGAC
4TMED2 F GACTCCAAAAATAGTGATGTTCAC
4TMED2 R GCTGTCATCGCCACTGCTAG
4CSDE1 F GCAATATTTGAGTATCACTGCG
4CSDE1 R AACCCCAGTTTCACGCAGTGC
Western blot analysis. Protein extracts were loaded onto a NuPAGE Tris-Acetate
Minigel 3–8% 1mm (Invitrogen) or onto a NuPAGE Bis-Tris minigel 4–12% 1mm
(Invitrogen). Running and blotting were performed in an XCell SureLock Minicell
(Invitrogen) according to the manufacturer’s instructions and proteins were
transferred to a nitrocellulose transfer membrane (Amersham Protran).
Membranes were blocked with 10% non-fat dry milk and incubated o/n with
primary antibodies. Protein detection was carried out with Clarity ECL Western
Blotting Substrate (Bio-Rad). Primary antibodies: anti-dystrophin (NCL-DYS1
Novocastra Laboratories, 1:40); anti-myogenin (sc-12732 Santa Cruz 1:1,000); anti-
MHC (anti-MF-20, 1:20), anti-MCK (sc-15161 Santa Cruz, 1:500 in TBST); anti-
actinin (ACTN sc-15335 Santa Cruz, 1:1000); and anti-glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (sc-365062 Santa Cruz, 1:10,000). Anti-CELF (ab50734
Abcam, 1:1,250). Anti-FLAG M2 (F1804 Sigma-Aldrich, 1:1,000). Secondary
antibodies: ImmunoPure Goat Anti-Rabbit IgG Peroxidase Conjugated (31460
Pierce, 1:5,000); ImmunoPure Goat Anti-Mouse IgG Peroxidase Conjugated
(31430 Pierce, 1:10,000); donkey anti-goat IgG-HRP (sc-2020 Santa Cruz, 1:5,000).
Uncropped scans of blots in Fig. 1a,b,d are shown in Supplementary Fig. 4.
Overexpression of CELF2a. Construct for the overexpression of CELF2a was
obtained by cloning CELF2a coding sequence in pCDNA3.1(þ ) plasmid
(Invitrogen). CELF2a coding sequence was amplified by PCR from WT myoblast
cDNA using the oligonucleotides: 50AAAAAAGCTTATGCGCTGTCCCAAATCC
GCT-30 and 50-AAAACTCGAGTCAGTAAGGTTTGCTGTCGTTTTTG-30 .
The italicized bases are HindIII and XhoI restriction sites. pFLAG-CELF2a was
obtained by inverse PCR using the oligos: 50-gtccttgtagtccatAAGCTTAAGTTT
AAACGCTAGC-30 and 50-gacgatgacaagATGCGCTGTCCCAAATCCGCTG-30 .
The lower case bases are the ones coding for the FLAG tag.
pLuc45 reporter construct and luciferase assays. The insert ‘45’ was obtained
by PCR from WT genomic DNA using the oligonucleotides: 50-AAGGAAAAAA
GCGGCCGCAAATACTTTGTTCATGTT-30 and 50-CCTTAATTAAACAATCAT
TTATAATTGC -30 . The italicized bases are NotI and PacI restriction sites. The
insert, made of the whole exon 45 flanked by 391 bp of intron 44 and 347 bp of
intron 45, was inserted into pcDNA3.1-Luc vector. Transfection efficiency of this
construct was assessed by cotransfection of pRLTK plasmid (Promega) encoding
for renilla luciferase gene. RLuc and FLuc activities were measured by Dual Glo
Luciferase assay (Promega).
RNA sequencing and bioinformatic analysis. Total RNA from GSD44, D44-1
and WT myoblasts and myotubes was isolated by Qiazol reagent and purified on
miRNeasy columns according to manufacturer instructions (Qiagen). Ribosomal
depletion and library preparation were carried out at Istituto di Genomica
Applicata (Udine) according to the Illumina Truseq protocol. Reads (2 100
paired end) were produced on an Illumina HiSeq 2000. After base calling (Casava)
and adaptor removal (Cutadapt), reads were alligned to the human genome (hg19)
using TopHat 2.0.11 and the resulting bam files used as input for MATS 3.0.8.
Ensembl GRCh37 was used as reference annotation. Exon skipping/inclusion
events detected by MATS with both counting spliced reads and exon coverage were
then filtered for false discovery rateo0.1 and concordance between the following
pairwise comparisons: GSD44 versus WT (myoblasts, GM #A) with GSD44 versus
D44-1 (myoblasts) and GSD44 versus WT (myotubes, DM#A) with GSD44 versus
D44-1 (myotubes).
CLIP assay. The RNP precipitation was performed using 5 106 human WT and
GSD44 myoblasts cultured in DM medium for 5 days, rinsed with PBS and UV
crosslinked once at 400mJ cm 2 in Spectrolinker XL-1000. Cell were harvested in
400 ml of PBS and 1.6ml of Nuclear isolation buffer (0.32M Sucrose; 10mM
Tris-HCl Ph 7.5; 5mM MgCl2; and 1% Triton X-100) and incubated for 20min on
ice. Nuclei were collected by centrifugation at 2500g for 15min and resuspended
in 1ml of RIP Buffer (150mM KCl; 25mM Tris-HCl Ph 7.4; 5mM EDTA;
0.5mM DTT; and 0.5% NP40). Nuclei were mechanically sheared using a dounce
homogenizer and debris were eliminated by centrifugation. A total of 5 mg of
Anti-CELF (ab50734 Abcam) and 5 mg of the control IgG antibodies were used for
the immunoprecipitation for 12 h at 4 C. A total of 40ml of protein G agarose
beads were added and incubated for 2 h at 4 C. Beads were washed three times
with RIP buffer and once with PBS. The beads were then treated with proteinase
K (Ambion) before the addition of Tryzol for the RNA extraction. The
oligonucleotides used in the RT–PCR analyses are listed below.
4DMD E10F GCAGTTCATTGATGGAGAGTG
4DMD E10 R CACCACTTCCACATCATTAGA
4DMD E44F GATTGGACAGATCTGTTGAGA
4DMD E45F ATGGCATTGGGCAGCGGCAAAC
4DMD E45R ACCTCCTGCCACCGCAGATTC
4IR F GCCATGTTGGCTAGGCTGGTCTC
4IR R GGCTTACACCACTGCGCTCAGC
4GAPDH F GGAAGGTGAAGGTCGGAGTC
4GAPDH R TTACCACAGTTAAAAGCAGCCC
Statistical analyses. Statistical significance of differences between means was
assessed by two-tailed t-test and Po0.05 was considered significant.
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